Centessa Pharmaceuticals plc
CNTA
$39.60
-$0.02-0.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.46% | 2.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.30% | -1.58% | |||
| Operating Income | -27.30% | 1.58% | |||
| Income Before Tax | -21.85% | -10.41% | |||
| Income Tax Expenses | -414.46% | -78.66% | |||
| Earnings from Continuing Operations | -20.54% | -9.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.54% | -9.03% | |||
| EBIT | -27.30% | 1.58% | |||
| EBITDA | -27.71% | 1.61% | |||
| EPS Basic | -13.91% | -8.63% | |||
| Normalized Basic EPS | -15.14% | -10.01% | |||
| EPS Diluted | -13.91% | -8.63% | |||
| Normalized Diluted EPS | -15.14% | -10.01% | |||
| Average Basic Shares Outstanding | 5.83% | 0.36% | |||
| Average Diluted Shares Outstanding | 5.83% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||